Assertio completes merger with Zydus Lifesciences; common stock delisted
Assertio Holdings completed its merger with Zydus Lifesciences on June 16, 2026, following a tender offer that closed on June 15, 2026, with 4,286,488 shares (approximately 66.32% of outstanding shares) validly tendered. Assertio stockholders received $23.50 per share in cash. The company became a wholly owned subsidiary of Zydus Lifesciences and its common stock was delisted from Nasdaq. Convertible noteholders have the right to require repurchase at 100% of principal plus accrued interest on July 17, 2026, or to convert notes into approximately $382.58 in cash per $1,000 principal amount.
Key facts
- Merger completion effective June 16, 2026
- 4,286,488 shares tendered, representing approximately 66.32% of outstanding shares
- $23.50 per share in cash paid to stockholders
- Assertio became wholly owned subsidiary of Zydus Lifesciences
- Common stock delisted from Nasdaq effective June 16, 2026
- $40,000,000 aggregate principal amount of 6.50% Convertible Senior Notes due 2027 outstanding
- Fundamental Change Repurchase Date: July 17, 2026
- Convertible noteholders receive approximately $382.58 in cash per $1,000 principal amount upon conversion
- Conversion Period expires July 16, 2026 at 5:00 p.m. Eastern Time
- Agreement and Plan of Merger dated May 13, 2026; parent: Zydus Worldwide DMCC
Why it matters
The completed acquisition terminates Assertio's independent public company status, ending stockholder equity participation and Nasdaq listing, while triggering fundamental-change repurchase and conversion rights for holders of the company's $40 million convertible notes.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-16. Not investment advice. View the source filing on SEC.gov →